Entrada Therapeutics (TRDA) Other Working Capital Changes (2020 - 2026)

Entrada Therapeutics' Other Working Capital Changes history runs 5 years deep, the most recent figure standing at -$1.2 million for Q1 2026.

• In Q1 2026, Other Working Capital Changes rose 46.52% year-over-year to -$1.2 million; the TTM figure through Mar 2026 stood at -$7.2 million (up 23.19% YoY), while the FY2025 annual figure was -$8.3 million, up 8.29% from the prior year.
• Other Working Capital Changes for Q1 2026 stood at -$1.2 million, up from -$1.5 million in the prior quarter.
• The five-year high for Other Working Capital Changes was $211.6 million in Q1 2023, with the low at -$222.5 million in Q2 2023.
• The 5-year median for Other Working Capital Changes is $2.5 million (2026), against an average of $1.9 million.
• The sharpest annual moves came in 2023 and 2024: Other Working Capital Changes jumped 141.76% in 2023, then plunged 350.54% in 2024.
• Entrada Therapeutics' Other Working Capital Changes stood at -$2.0 million in 2022, then surged by 141.76% to $841000.0 in 2023, then slumped by 350.54% to -$2.1 million in 2024, then soared by 30.33% to -$1.5 million in 2025, then increased by 19.48% to -$1.2 million in 2026.
• Business Quant data shows TRDA's Other Working Capital Changes at -$1.2 million in Q1 2026, -$1.5 million in Q4 2025, and -$2.3 million in Q3 2025.